Trial Profile
Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of SHR9549 in Women With ER Positive HER2 Negative Advanced Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 02 Sep 2022
Price :
$35
*
At a glance
- Drugs SHR 9549 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 29 Aug 2022 Status changed from not yet recruiting to discontinued since sponsor's R & D Strategy Adjustment.
- 30 Jul 2018 New trial record